Jennifer H. Mak, Chief Accounting Officer of Axon Enterprise, Inc., reported a sale of 1134 shares of common stock on December 19, 2025. The transaction was executed at a price of $600 per share, totaling $680,400. Following this transaction, Ms. Mak owns 13739.824 shares of common stock. This sale was conducted under ...

This Form 4 filing reports that Mary Louise Bohn, President of Titleist Golf Balls at Acushnet Holdings Corp., acquired 548.3 shares of common stock through dividend equivalent rights on December 19, 2025. The shares were acquired at a price of $82.45 per share, representing dividend equivalent rights accrued in connec...

This filing details a transaction by Roland A. Giroux, Executive Vice President, Chief Legal Officer and Corporate Secretary of Acushnet Holdings Corp. On December 19, 2025, Mr. Giroux acquired 141.46 shares of Common Stock under the Issuer's deferred compensation plan, specifically related to dividend equivalent right...

This filing details a transaction by Gregory A. Hewett, a director at Acushnet Holdings Corp. On December 19, 2025, Mr. Hewett acquired 90.81 shares of Common Stock, with a transaction price of $82.45 per share. This acquisition is related to dividend equivalent rights in connection with the Issuer's quarterly dividend...

David Eugene Maher, President and CEO of Acushnet Holdings Corp. (GOLF), reported a transaction on December 19, 2025. Maher acquired 2234.93 shares of Common Stock at a price of $82.45 per share. This acquisition was part of dividend equivalent rights related to restricted and performance stock units under the company'...

This Form 4 filing details a transaction by Jan Singer, a director at Acushnet Holdings Corp. (GOLF). On December 19, 2025, Singer acquired 33.23 shares of Common Stock, indicated by transaction code "A". The acquisition price was $82.45 per share. Following this transaction, Singer now owns 11699.55 shares. The acquir...

This filing details a transaction by Steven Tishman, a director at Acushnet Holdings Corp. (GOLF), on December 19, 2025. Tishman acquired 90.81 shares of Common Stock, represented by dividend equivalent rights on restricted stock units, at a price of $82.45 per share. This acquisition brings his total ownership to 40,2...

This filing details a transaction by Yoon Yoon Soo (Gene), a director and 10% owner of Acushnet Holdings Corp. The transaction, which occurred on December 19, 2025, involved the acquisition of 60.71 shares of Common Stock at a price of $82.45 per share. These shares are related to dividend equivalent rights in connecti...

This filing details stock transactions by Aristotle N. Balogh, Chief Technology Officer of Airbnb, Inc., on December 19, 2025. Balogh disposed of 650 shares of Class A Common Stock at a weighted average price of $134.15, acquired 1915 shares at $122.41, and disposed of an additional 1915 shares at prices ranging from $...

This Form 4 filing details a transaction by John Gill, a director at Altimmune, Inc. On December 23, 2025, Mr. Gill acquired 12,500 shares of the company's common stock through a purchase transaction (Code "P"). The price per share was $4.10, resulting in a total transaction value of $51,250. Following this transaction...

William B. Horne, a director of Alzamend Neuro, Inc. (ALZN), sold all 3,333 shares of common stock on December 19, 2025, at a price of $2.1178 per share. This transaction resulted in Horne holding zero shares following the sale. The Form 4 filing, signed on December 23, 2025, indicates that Horne is a director of the c...

This filing details a transaction by Richard Busch, a director at American Bitcoin Corp. (ABTC), on December 22, 2025. Mr. Busch acquired 101,000 shares of Class A Common Stock at a price of $1.98 per share. Following this transaction, Mr. Busch now directly owns 1,000,975 shares of the company's stock. The transaction...

Karen Firestone, a director at Amylyx Pharmaceuticals, Inc. (AMLX), acquired 8,100 shares of common stock on December 23, 2025. The transaction was executed at a price of $12.45 per share. Following this acquisition, Ms. Firestone now owns 63,100 shares of the company's common stock. The filing, designated as Form 4, i...

This filing details a series of stock sales by Christopher Richard Anzalone, the Chief Executive Officer and a Director of Arrowhead Pharmaceuticals, Inc. The transactions occurred on December 19 and December 22, 2025. A total of 25,031 shares of common stock were sold. These sales were conducted under a 10b5-1 trading...

Jane Henderson, Chief Financial Officer of Apogee Therapeutics, Inc., reported a sale of 1500 shares of common stock on December 19, 2025. The transaction was executed at a price of $80.00 per share, resulting in a total sale value of $120,000. This sale was conducted under a Rule 10b5-1 trading plan adopted on Septemb...

This filing details insider transactions for Walter D. Bay, General Counsel at Arthur J. Gallagher & Co., on December 19, 2025. Mr. Bay acquired 15,850 shares of common stock at a price of $79.59 per share. Concurrently, he disposed of 15,850 shares of common stock at $255.00 per share and disposed of 1,724 shares with...

This filing details stock transactions by Sonalee Elizabeth Parekh, Chief Financial Officer of Asana, Inc. On December 22, 2025, Ms. Parekh sold 83,656 shares of Class A Common Stock at $14.31 per share. This sale was conducted under the company's policy to cover tax obligations incurred from the vesting of Restricted ...

Eleanor B. Lacey, GC and Corporate Secretary of Asana, Inc., reported the sale of 55,234 shares of Class A Common Stock on December 22, 2025, for $14.31 per share, and 45,463 shares on December 23, 2025, for $13.5459 per share. These transactions were executed under a Rule 10b5-1 trading plan. The sales were made to co...

This filing details significant transactions by Justin Rosenstein, a director at Asana, Inc., primarily involving Class A and Class B Common Stock. On December 19, 2025, Rosenstein acquired 3,000,000 shares of Class A Common Stock and concurrently disposed of 3,000,000 shares of Class B Common Stock, which are converti...

This filing details significant transactions by Perceptive Advisors LLC and its affiliated entities concerning Athira Pharma, Inc. (ATHA). On December 23, 2025, these entities acquired a substantial number of securities, including common stock and various warrants (Pre-Funded, Series A, and Series B). The transactions ...

Gregory M. Shepard entered into a multi-tranche, prepaid variable share forward sale transaction involving 425,000 shares of Atlas Energy Solutions Inc. common stock. The transaction, dated December 19, 2025, obligates Shepard to deliver these shares, or an equivalent cash amount, to an unaffiliated third-party buyer b...

Michael Cannon-Brookes, CEO, Co-Founder, and 10% owner of Atlassian Corp, reported the disposition of 5625 Class A Common Stock shares on December 19, 2025. The transactions were executed under a Rule 10b5-1 trading plan at prices ranging from $160.76 to $165.59, with a weighted-average price of $161.33 for the first t...

Michael Cannon-Brookes, CEO, Co-Founder, and 10% owner of Atlassian Corp, reported a series of dispositions of Class A Common Stock on December 22, 2025. These transactions were executed under a Rule 10b5-1 trading plan. A total of 8665 shares were sold across multiple trades at prices ranging from $161.44 to $165.46. ...

On December 23, 2025, Michael Cannon-Brookes, CEO, Co-Founder, and 10% owner of Atlassian Corp, reported the sale of 8,270 shares of Class A Common Stock through a Rule 10b5-1 trading plan. The sales occurred at prices ranging from $158.53 to $163.42, with a weighted-average price of approximately $161.37. These transa...

On December 19, 2025, Scott Farquhar, a 10% owner and director of Atlassian Corp, reported the sale of 5625.0 shares of Class A Common Stock through a Rule 10b5-1 trading plan. The transactions were executed at prices ranging from $160.76 to $164.71, with a weighted-average price of approximately $162.67. These sales r...